643 related articles for article (PubMed ID: 34072831)
1. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
2. BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death.
Ko HJ; Chiou SJ; Tsai CY; Loh JK; Lin XY; Tran TH; Hou CC; Cheng TS; Lai JM; Chang PM; Wang FS; Su CL; Huang CF; Hong YR
Cell Commun Signal; 2022 Dec; 20(1):200. PubMed ID: 36575468
[TBL] [Abstract][Full Text] [Related]
3. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
5. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
6. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
[TBL] [Abstract][Full Text] [Related]
7. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
8. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
9. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
11. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
13. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
14. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
15. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
16. Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway.
Zou Y; Xu L; Wang W; Zhu X; Lin J; Li H; Chen J; Xu W; Gao H; Wu X; Yin Z; Wang Q
Phytomedicine; 2024 Jul; 129():155714. PubMed ID: 38723526
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Cai T; Liu Y; Xiao J
Cancer Med; 2018 Apr; 7(4):1404-1415. PubMed ID: 29479863
[TBL] [Abstract][Full Text] [Related]
19. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]